Neoadjuvant immunotherapy in resectable non-small-cell lung cancer

The advent of immune checkpoint inhibition has pushed the treatment paradigm for resectable non-small-cell lung cancer (NSCLC) toward neoadjuvant therapy. A growing number of promising trials have examined the utility of neoadjuvant immunotherapy, both alone and in combination with other modalities...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Lanyi Nora, Wei, Alexander Z., Shu, Catherine A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052589/
https://www.ncbi.nlm.nih.gov/pubmed/37007633
http://dx.doi.org/10.1177/17588359231163798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052589/
https://www.ncbi.nlm.nih.gov/pubmed/37007633
http://dx.doi.org/10.1177/17588359231163798

Ejemplares similares